Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids

• Published in: Cancer gene therapy 2015-10, Vol.22 (10), p.496-505
• Main Authors: Somnay, Y R, Dull, B Z, Eide, J, Jaskula-Sztul, R, Chen, H
• Format: Article
• Language: English
• Subjects: 13/31; 42/109; 42/34; 42/89; 45/41; 631/67/1059/602; 631/67/1459/1963; 82/80; 96/2; Apoptosis; Apoptosis - drug effects; Apoptosis - genetics; ASCL1 protein; Basic Helix-Loop-Helix Transcription Factors - genetics; Basic Helix-Loop-Helix Transcription Factors - metabolism; Biological activity; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer treatment; Carcinoid Tumor - genetics; Carcinoid Tumor - metabolism; Carcinoid Tumor - pathology; Caspase-3; Cell cycle; Cell Cycle Checkpoints - drug effects; Cell Cycle Checkpoints - genetics; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell Proliferation - genetics; Chromogranin A - genetics; Chromogranin A - metabolism; Cyclin B1; Cyclin-dependent kinase inhibitor p21; Cyclin-dependent kinase inhibitor p27; Dose-Response Relationship, Drug; Flavonoids; Flavonoids - pharmacology; G2 phase; Gene Expression; Gene Expression Regulation, Neoplastic - drug effects; Gene Therapy; Genetic aspects; Health aspects; Humans; Immunoblotting; Medical schools; Monosaccharides; Morbidity; Mortality; Neoplasia; Neuroendocrine tumors; Neurosecretory Systems - drug effects; Neurosecretory Systems - metabolism; Neurosecretory Systems - pathology; original-article; Phenotypes; Prevention; Properties; Propidium iodide; Receptor, Notch1 - genetics; Receptor, Notch1 - metabolism; Reverse Transcriptase Polymerase Chain Reaction; Ribose; RNA; RNA Interference; siRNA; Synaptophysin; Time Factors; Transcription factors; Tumors; Western blotting
• ISSN: 0929-1903; 1476-5500
• DOI: 10.1038/cgt.2015.49

Carcinoids are neuroendocrine neoplasms that cause significant morbidity and mortality and for which few effective therapies are available. Given the recent identification of the anticancer flavonoid chrysin, we sought to investigate its therapeutic potential in carcinoids. Here we report chrysin’s ability to modulate the achaete-scute complex-like 1 (ASCL1), a neuroendocrine-specific transcription factor highly implicated in the malignant phenotype of carcinoids and other neuroendocrine cancers. Moreover, we elucidate the role of ASCL1 in carcinoid growth and bioactivity. Treatment of two carcinoid cell lines (BON and H727) with varying chrysin concentrations suppressed cell proliferation, while reducing expression of ASCL1 and the neuroendocrine biomarker chromogranin A (CgA), demonstrated by western blotting. Propidium iodide and phycoerythrin AnnexinV/7-aminoactinomycin D staining and sorting following chrysin treatment revealed S/G2 phase arrest and apoptosis, respectively. This was corroborated by chrysin-induced cleavage of caspase-3 and poly ADP-ribose polymerase and activation of p21 Waf1/Cip1 . Furthermore, direct ASCL1 knockdown with an ASCL1 -specific small interfering RNA inhibited CgA and synaptophysin expression as well as carcinoid proliferation, while also reducing cyclin B1 and D1 and increasing p21 Waf1/Cip1 and p27 Kip1 expression, suggesting an arrest of the cell cycle. Collectively, these findings warrant the deliberation of targeted ASCL1 suppression by chrysin or other agents as a therapeutic approach for carcinoid management.